Innate Pharma S.A.
IPHA
Rank in Stocks
#17557
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Share Price
$1.51
Last synced: 2026-11-09
Market Cap
$163.72M
Change (1 day)
4.86%
Change (1 year)
-29.44%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Innate Pharma S.A. (IPHA)
Category
Healthcare
Operating Margin for Innate Pharma S.A. (IPHA)
Operating Margin as of November 2026 TTM: -5,133.30%
According to Innate Pharma S.A.'s latest financial reports, its current operating margin (TTM) is -5,133.30%. At the end of 2025 the company had an operating margin of -2,058.02%.
Operating Margin history for Innate Pharma S.A. from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -5,133.30% | 149.43% |
| 2025 | -2,058.02% | 403.66% |
| 2024 | -408.61% | 1,573.95% |
| 2023 | -24.41% | -50.81% |
| 2022 | -49.62% | -87.43% |
| 2021 | -394.86% | -25,574.84% |
| 2020 | 1.55% | -103.95% |
| 2019 | -39.22% | -709.01% |
| 2018 | 6.44% | -105.26% |
| 2017 | -122.53% | -1,008.98% |
| 2016 | 13.48% | -122.41% |
| 2015 | -60.16% | -97.27% |
| 2014 | -2,201.32% | 9,727.32% |
| 2013 | -22.40% | -31.35% |
| 2012 | -32.63% | -49.40% |
| 2011 | -64.48% | -79.65% |
| 2010 | -316.90% | 57.40% |
| 2009 | -201.33% | 136.41% |
| 2008 | -85.16% | 33.86% |
| 2007 | -63.62% | -45.55% |
| 2006 | -116.85% | -76.32% |
| 2005 | -493.46% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.97% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Innate Pharma S.A.'s operating margin
What is Innate Pharma S.A.'s operating margin?
Innate Pharma S.A.'s operating margin is -5,133.30%, as of Nov 2026.
What was Innate Pharma S.A.'s operating margin in 2025?
In 2025, Innate Pharma S.A.'s operating margin was -2,058.02%, compared with -408.61% in 2024.
How has Innate Pharma S.A.'s operating margin changed since 2020?
From 2020 to 2025, Innate Pharma S.A.'s operating margin was highest in 2020 (1.55%) and lowest in 2025 (-2,058.02%).
How does Innate Pharma S.A.'s operating margin compare with similar companies?
Innate Pharma S.A.'s operating margin (-5,133.30%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.